Relmada Therapeutics Inc (NAS:RLMD)
$ 3.05 -0.06 (-1.93%) Market Cap: 92.03 Mil Enterprise Value: 10.23 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 31/100

Relmada Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 04:30PM GMT
Release Date Price: $26.02 (+0.85%)
Rahul Sood

Good afternoon, everyone. This is Rahul Sood here from Morgan Stanley Healthcare Investment Banking. We are joined today by Sergio Traversa, Chief Executive Officer of Relmada. Very honored and very pleased to have you join us, Sergio.

Before I turn it over to you, I would like to remind of 2 things to the audience here. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

The second housekeeping item is we will be asking the audience to submit their questions through the question portal. I see there are a few that are coming in already. We'll use this time, Sergio, to, a, have you walk through the high -- the key points about the company, what's happening at the moment and the -- and any upcoming data points that you would ask the investors to focus on. And then we can get into some of the more fireside Q&A format after that.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot